Amerikanische Gesellschaft für Hirudotherapie

Enzymatic production of specifically distributed hyaluronan oligosaccharides

Research article published in Carbohydr Polym (2015)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Speichel-PharmakologieArzneimittelentwicklungYuan P et al. · Carbohydr Polym, 2015

Abstract

High-molecular-mass hyaluronan (HA) was controllably depolymerized in pure aqueous solution with recombinant leech hyaluronidase (HAase). The HAase concentration per unit HA and hydrolysis time played important roles in molecular mass distribution. By modulating the concentrations of HAase and controlling the hydrolysis time, any molar-mass-defined HA oligomers could be efficiently and specifically produced on a large scale (40 g/L), such as HA oligosaccharides with weight-average molar mass of 4000, 10,000, and 30,000Da and end hydrolysates containing only HA6 and HA4. High performance liquid chromatography-size exclusion chromatography, polyacrylamide gel electrophoresis, capillary zone electrophoresis, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry confirmed low polydispersity of the produced molar-mass-defined HA oligosaccharides. Therefore, large-scale production of defined HA oligosaccharides with narrow molecular mass distribution will significantly promote progress in related research and its potential applications.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsBiocatalysisChromatography, GelChromatography, High Pressure LiquidElectrophoresis, CapillaryElectrophoresis, Polyacrylamide GelEnzyme StabilityFermentationHyaluronic AcidHyaluronoglucosaminidaseHydrolysisLeeches

Zusammenfassung

Recombinant leech hyaluronidase produces molar-mass-defined HA oligomers (4000, 10000, 30000 Da) at 40 g/L; large-scale production for industrial applications.

Warum dies für die Hirudotherapie relevant ist

This study demonstrated that recombinant leech hyaluronidase could controllably depolymerize high-molecular-mass hyaluronan in pure aqueous solution to efficiently produce molar-mass-defined hyaluronan oligosaccharides at large scale (up to 40 g/L), with multiple analytical techniques confirming low polydispersity of the products. The use of a leech-derived enzyme gives this work relevance to ASH's domain by contributing to the biochemical and biotechnological characterization of a leech enzyme. However, the study is purely biochemical and biotechnological in nature, using a recombinant enzyme rather than live leeches, and does not address hirudotherapy, clinical leech applications, or the broader leech secretome.

Zitation

Enzymatic production of specifically distributed hyaluronan oligosaccharides.

Yuan P et al. · Carbohydr Polym, 2015

DOI

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Salivary Gland SecretionAnti-Inflammatory MechanismsSalivary ComplexDrug PipelineDrug DevelopmentDirect Thrombin InhibitorsOtolaryngology

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.